FDA panel to weigh Amgen, J&J drug limits

Once again, FDA's experts will wrangle over safe use of Amgen and Johnson & Johnson's blockbuster anemia drugs. In the wake of a study that raised new questions about the safety of Amgen's Aranesp, the agency is convening an advisory panel for advice on changing the anemia drugs' labeling to restrict their use in kidney patients who aren't yet on dialysis.